Hikma
-
Featured
Hikma delivers strong H1 performance and upgrades Group guidance
Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its interim results for the six months ended 30 June 2024. The Group reported revenue growth of 10% (10% in constant currency) to $1.569 billion (compared to $1.427 billion in H1 2023). We have made excellent progress in the first half of 2024 with growth…
Read More » -
Featured
Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced that it has recently signed an exclusive licencing agreement with AFT Pharmaceuticals (AFT) for the registration and commercialization of Combogesic® IV, an intravenous, opioid-free pain relief medicine for the short term symptomatic treatment of acute pain in adults and the reduction of fever, in Saudi Arabia, Jordan, and Iraq. It is…
Read More » -
Featured
Hikma and Guardant Health sign exclusive partnership agreement to bring transformative cancer diagnostic technology to the Middle East and North Africa
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive agreement with Guardant Health, Inc., a leading precision oncology company. Through the agreement, Hikma has the exclusive rights for commercialisation and marketing of Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in the Middle…
Read More » -
Health
Hikma continues strong momentum across the Group and upgrades guidance for 2023
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Riad Mishlawi, Chief Executive Officer of Hikma, said: “The good momentum during the first half has continued, enabling us to upgrade full year guidance in two of our three businesses. Our Branded business is performing exceptionally well on an underlying…
Read More » -
Africa
Good momentum across all businesses and updated Generics guidance
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting. Said Darwazah, Hikma’s Executive Chairman and CEO, said: “Hikma has had a good start to the year. Our Injectables and Branded businesses continue to perform well reflecting our diversified portfolio of products and manufacturing…
Read More » -
Africa
Hikma delivers a resilient underlying performance in 2022
Amman, Jordan — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its preliminary audited results for the year ended 31 December 2022. In 2022, the Group reported revenue of $2.517 billion (slightly down from $2.553 billion in 2021), backed by its resilient business model and good performance from the Injectables and Branded businesses, and offset by…
Read More » -
Africa
Hikma and Celltrion Healthcare sign new exclusive licensing agreement for Vegzelma® for the Middle East and North Africa region
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing agreement with Celltrion Healthcare Co., Ltd, a global biopharmaceutical company, for Vegzelma® (CT-P16, bevacizumab). Under the terms of the agreement, Celltrion Healthcare will be responsible for the development, manufacturing and supply of Vegzelma® and Hikma will be responsible for the commercialisation of the product in…
Read More » -
Africa
Hikma and Junshi Biosciences sign exclusive licensing agreement for cancer treatment drug toripalimab for the Middle East and North Africa region
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces a new exclusive licensing and commercialization agreement with Junshi Biosciences, an innovation-driven biopharmaceutical company, for toripalimab in the Middle East and North Africa (MENA). Under the terms of the agreement, Hikma has an exclusive license to develop and commercialize toripalimab injection in all its MENA markets.…
Read More » -
Africa
Hikma and Celltrion Healthcare sign exclusive licensing agreement for ustekinumab for the Middle East and North Africa region
London, England — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing agreements with Celltrion Healthcare Co., Ltd. for CT-P43 (ustekinumab). CT-P43 is a monoclonal antibody that is a proposed biosimilar to Janssen’s Stelara®. Under the terms of the agreement, Hikma will have exclusive rights to commercialise CT-P43 in all of its MENA markets and Celltrion Healthcare will…
Read More » -
Africa
Hikma and Adalvo Sign Exclusive Licensing Agreement to Commercialise Allergic Rhinitis Medication across MENA Markets
Amman, Jordan — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with Adalvo to commercialise a nasal spray medication used to treat an increasingly prevalent respiratory disease; allergic rhinitis (AR). The exclusive licensing and supply agreement with Adalvo expands Hikma’s respiratory portfolio in MENA. The licensed product is a combination treatment in a single advanced…
Read More » -
Africa
Hikma’s diversified business delivers resilient H1 performance
London, United Kingdom — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its interim results for the six months ended 30 June 2022. During the first half of 2022, core group revenue was flat at $1.213 billion (compared to H1 2021: $1.216 billion) as the strong performance from our Injectables and Branded businesses offset the impact…
Read More » -
Africa
Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with Celltrion, Inc. and Celltrion Healthcare, Inc. (Celltrion) for YuflymaTM (CT-P17), the first adalimumab biosimilar with a high concentration, low-volume and citrate-free formulation. This latest agreement provides Hikma with exclusive rights to commercialise YuflymaTM in all of its MENA markets, strengthening its strategic…
Read More » -
Middle East
Hikma and Melinta Therapeutics sign exclusive licensing agreement for two novel anti-infectives for the Middle East and North Africa region
London, United Kingdom, 08 May 2021: Hikma Pharmaceuticals PLC (Hikma) and Melinta Therapeutics (Melinta) today announced they have entered into an exclusive licensing agreement for Vabomere® (meropenem and vaborbactam) and Orbactiv® (oritavancin), two novel anti-infective injectable products, for the Middle East and North Africa (MENA) region. In the United States, Orbactiv® is indicated for the treatment of adult patients with…
Read More »
